PURPOSE: To determine the outcomes, with particular attention to toxicity, of children with Down syndrome (DS) and acute myeloid leukemia (AML) treated on Pediatric Oncology Group (POG) protocol 9421. PATIENTS AND METHODS: Children with DS and newly diagnosed AML (n = 57) were prospectively enrolled onto the standard-therapy arm of POG 9421 and were administered five cycles of chemotherapy, which included daunorubicin 135 mg/m(2) and mitoxantrone 80 mg/m(2). Outcomes and toxicity were evaluated prospectively and were compared with the non-DS-AML cohort (n = 565). A retrospective chart review was performed to identify adverse cardiac events. RESULTS: In the DS-AML group, 54 patients (94.7%) entered remission. One experienced induction failure and two died. Of the 54 who entered remission, three relapsed and six died as a result of other causes. The remission induction rate was similar in the non-DS-French-American-British (FAB) M7 (91.7%) and non-DS-non-M7 (89.3%) groups. The 5-year overall survival was significantly better in the DS-AML group (78.6%) than in the non-DS-M7 (36.3%) or the non-DS-non-M7 (51.8%) groups (P < .001). No age-related difference in 5-year, event-free survival was seen between patients younger than 2 years (75.8%) and those aged 2 to 4 years (78.3%). Symptomatic cardiomyopathy developed in 10 patients (17.5%) with DS-AML during or soon after completion of treatment; three died as a result of congestive heart failure. CONCLUSION: The POG 9421 treatment regimen was highly effective in both remission induction and disease-free survival for patients with DS-AML. However, there was a high incidence of cardiomyopathy, which supports current strategies for dose reduction of anthracyclines in this patient population.
PURPOSE: To determine the outcomes, with particular attention to toxicity, of children with Down syndrome (DS) and acute myeloid leukemia (AML) treated on Pediatric Oncology Group (POG) protocol 9421. PATIENTS AND METHODS: Children with DS and newly diagnosed AML (n = 57) were prospectively enrolled onto the standard-therapy arm of POG 9421 and were administered five cycles of chemotherapy, which included daunorubicin 135 mg/m(2) and mitoxantrone 80 mg/m(2). Outcomes and toxicity were evaluated prospectively and were compared with the non-DS-AML cohort (n = 565). A retrospective chart review was performed to identify adverse cardiac events. RESULTS: In the DS-AML group, 54 patients (94.7%) entered remission. One experienced induction failure and two died. Of the 54 who entered remission, three relapsed and six died as a result of other causes. The remission induction rate was similar in the non-DS-French-American-British (FAB) M7 (91.7%) and non-DS-non-M7 (89.3%) groups. The 5-year overall survival was significantly better in the DS-AML group (78.6%) than in the non-DS-M7 (36.3%) or the non-DS-non-M7 (51.8%) groups (P < .001). No age-related difference in 5-year, event-free survival was seen between patients younger than 2 years (75.8%) and those aged 2 to 4 years (78.3%). Symptomatic cardiomyopathy developed in 10 patients (17.5%) with DS-AML during or soon after completion of treatment; three died as a result of congestive heart failure. CONCLUSION: The POG 9421 treatment regimen was highly effective in both remission induction and disease-free survival for patients with DS-AML. However, there was a high incidence of cardiomyopathy, which supports current strategies for dose reduction of anthracyclines in this patient population.
Authors: Christian M Zwaan; Gertjan J L Kaspers; Rob Pieters; Karel Hählen; Gritta E Janka-Schaub; Christina H van Zantwijk; Dieuwke R Huismans; Esther de Vries; Marianne G Rots; Godefridus J Peters; Gerrit Jansen; Ursula Creutzig; Anjo J P Veerman Journal: Blood Date: 2002-01-01 Impact factor: 22.113
Authors: S Kojima; M Sako; K Kato; G Hosoi; T Sato; A Ohara; K Koike; Y Okimoto; S Nishimura; Y Akiyama; T Yoshikawa; E Ishii; J Okamura; M Yazaki; Y Hayashi; M Eguchi; I Tsukimoto; K Ueda Journal: Leukemia Date: 2000-05 Impact factor: 11.528
Authors: Y Ravindranath; E Abella; J P Krischer; J Wiley; S Inoue; M Harris; A Chauvenet; C S Alvarado; R Dubowy; A K Ritchey Journal: Blood Date: 1992-11-01 Impact factor: 22.113
Authors: Alan S Gamis; William G Woods; Todd A Alonzo; Allen Buxton; Beverly Lange; Dorothy R Barnard; Stuart Gold; Franklin O Smith Journal: J Clin Oncol Date: 2003-07-28 Impact factor: 44.544
Authors: S E Lipshultz; S R Lipsitz; S M Mone; A M Goorin; S E Sallan; S P Sanders; E J Orav; R D Gelber; S D Colan Journal: N Engl J Med Date: 1995-06-29 Impact factor: 91.245
Authors: James L Kalabus; Carrie C Sanborn; Raqeeb G Jamil; Qiuying Cheng; Javier G Blanco Journal: Drug Metab Dispos Date: 2010-08-20 Impact factor: 3.922
Authors: Saro H Armenian; Melissa M Hudson; Renee L Mulder; Ming Hui Chen; Louis S Constine; Mary Dwyer; Paul C Nathan; Wim J E Tissing; Sadhna Shankar; Elske Sieswerda; Rod Skinner; Julia Steinberger; Elvira C van Dalen; Helena van der Pal; W Hamish Wallace; Gill Levitt; Leontien C M Kremer Journal: Lancet Oncol Date: 2015-03 Impact factor: 41.316
Authors: Adolfo Quiñones-Lombraña; Daniel Ferguson; Rachael Hageman Blair; James L Kalabus; Almedina Redzematovic; Javier G Blanco Journal: Pharm Res Date: 2014-02-22 Impact factor: 4.200
Authors: Erik Hefti; Adolfo Quiñones-Lombraña; Almedina Redzematovic; Jeffrey Hui; Javier G Blanco Journal: Mitochondrial DNA A DNA Mapp Seq Anal Date: 2014-06-18 Impact factor: 1.514